Montelukast as an Alternative to Low-Dose Inhaled Corticosteroids in the Management of Mild Asthma (The SIMPLE Trial): An Open-Label Effectiveness ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009

AUTHORS

R Andrew McIvor, Alan Kaplan, Caroline Koch, John S Sampalis

ABSTRACT

OBJECTIVE: To evaluate the effectiveness of montelukast as monotherapy for patients with mild asthma who remain uncontrolled or unsatisfied while on inhaled corticosteroid (ICS) monotherapy. DESIGN: A multicentre, open-label study. Patients (six years of age or older) had ICS therapy discontinued and were treated with orally administered montelukast once daily for six weeks. MAIN OUTCOME MEASURES: The primary outcome measure was the rate at which asthma symptom control was achieved or maintained after six weeks of treatment. The secondary outcome measures were to compare compliance and physician satisfaction, and to further assess the safety and tolerability of montelukast. RESULTS: Of the 534 patients enrolled, 481 (90.1%) completed the study. Mean (+/- SD) age was 27.8+/-19.0 years. The number of patients with uncontrolled symptoms decreased from 455 (85.2%) at baseline to 143 (26.8%) at week 6 (P<0.001), and mean Asthma Control Questionnaire score decreased from 1.4+/-0.8 to 0.6+/-0.6 (P<0.001), representing a clinically significant improvement. Of the 79 patients with controlled asthma symptoms at baseline, 73.4% maintained asthma control at week 6. Compliance to asthma therapy increased from 41% at baseline for ICS to 88% at week 6 for montelukast (P<0.001). Physician satisfaction with treatment increased from 43% to 85% (P<0.001) and patient satisfaction increased from 45% at baseline to 94% at week 6. No serious adverse events were reported over the course of the study. CONCLUSION: Montelukast is an effective and well-tolerated alternative to ICS treatment in patients with mild asthma who are uncontrolled or unsatisfied with low-dose ICS therapy. More... »

PAGES

11a-16a

Identifiers

URI

http://scigraph.springernature.com/pub.10.1155/2009/429482

DOI

http://dx.doi.org/10.1155/2009/429482

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041046874

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19557207


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acetates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Asthmatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucocorticoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Compliance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "McMaster University", 
          "id": "https://www.grid.ac/institutes/grid.25073.33", 
          "name": [
            "Firestone Institute of Respiratory Health, McMaster University, Hamilton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McIvor", 
        "givenName": "R Andrew", 
        "id": "sg:person.01353722471.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353722471.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "York Central Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417373.5", 
          "name": [
            "York Central Hospital, Richmond Hill, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaplan", 
        "givenName": "Alan", 
        "id": "sg:person.010455635571.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010455635571.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.292545.d", 
          "name": [
            "Merck Frosst Canada Limited, Kirkland, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koch", 
        "givenName": "Caroline", 
        "id": "sg:person.01274333640.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274333640.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McGill University", 
          "id": "https://www.grid.ac/institutes/grid.14709.3b", 
          "name": [
            "JSS Medical Research Inc., Montreal, Canada", 
            "Faculty of Medicine, McGill University, Montreal, Quebec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sampalis", 
        "givenName": "John S", 
        "id": "sg:person.01214767574.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214767574.40"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009", 
    "datePublishedReg": "2009-01-01", 
    "description": "OBJECTIVE: To evaluate the effectiveness of montelukast as monotherapy for patients with mild asthma who remain uncontrolled or unsatisfied while on inhaled corticosteroid (ICS) monotherapy.\nDESIGN: A multicentre, open-label study. Patients (six years of age or older) had ICS therapy discontinued and were treated with orally administered montelukast once daily for six weeks.\nMAIN OUTCOME MEASURES: The primary outcome measure was the rate at which asthma symptom control was achieved or maintained after six weeks of treatment. The secondary outcome measures were to compare compliance and physician satisfaction, and to further assess the safety and tolerability of montelukast.\nRESULTS: Of the 534 patients enrolled, 481 (90.1%) completed the study. Mean (+/- SD) age was 27.8+/-19.0 years. The number of patients with uncontrolled symptoms decreased from 455 (85.2%) at baseline to 143 (26.8%) at week 6 (P<0.001), and mean Asthma Control Questionnaire score decreased from 1.4+/-0.8 to 0.6+/-0.6 (P<0.001), representing a clinically significant improvement. Of the 79 patients with controlled asthma symptoms at baseline, 73.4% maintained asthma control at week 6. Compliance to asthma therapy increased from 41% at baseline for ICS to 88% at week 6 for montelukast (P<0.001). Physician satisfaction with treatment increased from 43% to 85% (P<0.001) and patient satisfaction increased from 45% at baseline to 94% at week 6. No serious adverse events were reported over the course of the study.\nCONCLUSION: Montelukast is an effective and well-tolerated alternative to ICS treatment in patients with mild asthma who are uncontrolled or unsatisfied with low-dose ICS therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1155/2009/429482", 
    "inLanguage": [
      "fr"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1112076", 
        "issn": [
          "1198-2241", 
          "1916-7245"
        ], 
        "name": "Canadian Respiratory Journal", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl A", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "name": "Montelukast as an Alternative to Low-Dose Inhaled Corticosteroids in the Management of Mild Asthma (The SIMPLE Trial): An Open-Label Effectiveness Trial", 
    "pagination": "11a-16a", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c388a3ece3dd6fd1d0b244935fd43ef3a1eac47cf3e282e52adb023908adbfb9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19557207"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9433332"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1155/2009/429482"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041046874"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1155/2009/429482", 
      "https://app.dimensions.ai/details/publication/pub.1041046874"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000391.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1155/2009/429482"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1155/2009/429482'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1155/2009/429482'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1155/2009/429482'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1155/2009/429482'


 

This table displays all metadata directly associated to this object as RDF triples.

184 TRIPLES      20 PREDICATES      50 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1155/2009/429482 schema:about N05e0f0452f974c34aba35b5479269a92
2 N0e01b599ab654a7b87b198f8e9acb9a8
3 N1cd741c4c5944d0597194655b6006306
4 N1fa976c576754133a8fa9949d4bbbbf3
5 N2a5637d2f15c4b8ba44973a388f0d488
6 N2c822ad0dfe84f119da2b1a7ae3e8739
7 N31b4cff0047648d491af7edf72bd936e
8 N481be2f423f04b4793f55457368f07f4
9 N5f3d381ba1b4462fa7446ab793d15d63
10 N62ec77f11f0746659059a53402b74022
11 N8224e57c68804d10a00b08e2afcce7a7
12 N82aa5b93d3ef4a58a982c8a91a59772b
13 N83aeecefdd8c4f99ab06e863776776e8
14 N9730d7bc85ab4e4d9c7c22bfc5af31cd
15 N9a5dfbb6173847da890dce2c4942512d
16 Na49cc75a6f21499c8f0f3945952832b0
17 Nb2bb23f70f70490599c312ab7800c94d
18 Nb32337e4f53e4130a454d7f9116435c3
19 Nd0e1e409b0bf4913a4f808ce8ff7350e
20 Neee3b8fdcbab48fe837bcfc59af5f32c
21 Nf8961401df4845308f20c7ac037d08a1
22 anzsrc-for:11
23 anzsrc-for:1102
24 schema:author N66af63d860444d9bbb74a0be45488331
25 schema:datePublished 2009
26 schema:datePublishedReg 2009-01-01
27 schema:description OBJECTIVE: To evaluate the effectiveness of montelukast as monotherapy for patients with mild asthma who remain uncontrolled or unsatisfied while on inhaled corticosteroid (ICS) monotherapy. DESIGN: A multicentre, open-label study. Patients (six years of age or older) had ICS therapy discontinued and were treated with orally administered montelukast once daily for six weeks. MAIN OUTCOME MEASURES: The primary outcome measure was the rate at which asthma symptom control was achieved or maintained after six weeks of treatment. The secondary outcome measures were to compare compliance and physician satisfaction, and to further assess the safety and tolerability of montelukast. RESULTS: Of the 534 patients enrolled, 481 (90.1%) completed the study. Mean (+/- SD) age was 27.8+/-19.0 years. The number of patients with uncontrolled symptoms decreased from 455 (85.2%) at baseline to 143 (26.8%) at week 6 (P<0.001), and mean Asthma Control Questionnaire score decreased from 1.4+/-0.8 to 0.6+/-0.6 (P<0.001), representing a clinically significant improvement. Of the 79 patients with controlled asthma symptoms at baseline, 73.4% maintained asthma control at week 6. Compliance to asthma therapy increased from 41% at baseline for ICS to 88% at week 6 for montelukast (P<0.001). Physician satisfaction with treatment increased from 43% to 85% (P<0.001) and patient satisfaction increased from 45% at baseline to 94% at week 6. No serious adverse events were reported over the course of the study. CONCLUSION: Montelukast is an effective and well-tolerated alternative to ICS treatment in patients with mild asthma who are uncontrolled or unsatisfied with low-dose ICS therapy.
28 schema:genre research_article
29 schema:inLanguage fr
30 schema:isAccessibleForFree true
31 schema:isPartOf N464552ae3fca455eb84ee269abb6a779
32 N4c63b074694b43c983928ac68ac06285
33 sg:journal.1112076
34 schema:name Montelukast as an Alternative to Low-Dose Inhaled Corticosteroids in the Management of Mild Asthma (The SIMPLE Trial): An Open-Label Effectiveness Trial
35 schema:pagination 11a-16a
36 schema:productId N34736c38715c480e8a830fa58bfaffdc
37 N3c3b9ff9d411494b95491cf7723f5c7b
38 N3cb0d6551f904374b343c7406e5b6d55
39 N6338db29310d4c708f25d3f3981a6682
40 Nb027673fecab4cc690226d091ccef3dc
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041046874
42 https://doi.org/10.1155/2009/429482
43 schema:sdDatePublished 2019-04-10T22:16
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher N52af50bd4ba64db090ce3a0dabda48f4
46 schema:url http://link.springer.com/10.1155/2009/429482
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N05e0f0452f974c34aba35b5479269a92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Administration, Inhalation
52 rdf:type schema:DefinedTerm
53 N0e01b599ab654a7b87b198f8e9acb9a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Patient Compliance
55 rdf:type schema:DefinedTerm
56 N1cd741c4c5944d0597194655b6006306 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Young Adult
58 rdf:type schema:DefinedTerm
59 N1fa976c576754133a8fa9949d4bbbbf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Child
61 rdf:type schema:DefinedTerm
62 N2a5637d2f15c4b8ba44973a388f0d488 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Anti-Asthmatic Agents
64 rdf:type schema:DefinedTerm
65 N2c822ad0dfe84f119da2b1a7ae3e8739 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Female
67 rdf:type schema:DefinedTerm
68 N31b4cff0047648d491af7edf72bd936e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Follow-Up Studies
70 rdf:type schema:DefinedTerm
71 N34736c38715c480e8a830fa58bfaffdc schema:name readcube_id
72 schema:value c388a3ece3dd6fd1d0b244935fd43ef3a1eac47cf3e282e52adb023908adbfb9
73 rdf:type schema:PropertyValue
74 N3c3b9ff9d411494b95491cf7723f5c7b schema:name nlm_unique_id
75 schema:value 9433332
76 rdf:type schema:PropertyValue
77 N3cb0d6551f904374b343c7406e5b6d55 schema:name pubmed_id
78 schema:value 19557207
79 rdf:type schema:PropertyValue
80 N464552ae3fca455eb84ee269abb6a779 schema:issueNumber Suppl A
81 rdf:type schema:PublicationIssue
82 N481be2f423f04b4793f55457368f07f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Humans
84 rdf:type schema:DefinedTerm
85 N4c63b074694b43c983928ac68ac06285 schema:volumeNumber 16
86 rdf:type schema:PublicationVolume
87 N4e567f6168ee4c70b9911f9b6c743047 rdf:first sg:person.010455635571.89
88 rdf:rest N8a23f67906a04f1680a8a09eab07212a
89 N52af50bd4ba64db090ce3a0dabda48f4 schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N5f3d381ba1b4462fa7446ab793d15d63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Male
93 rdf:type schema:DefinedTerm
94 N62ec77f11f0746659059a53402b74022 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Treatment Outcome
96 rdf:type schema:DefinedTerm
97 N6338db29310d4c708f25d3f3981a6682 schema:name doi
98 schema:value 10.1155/2009/429482
99 rdf:type schema:PropertyValue
100 N66af63d860444d9bbb74a0be45488331 rdf:first sg:person.01353722471.20
101 rdf:rest N4e567f6168ee4c70b9911f9b6c743047
102 N8224e57c68804d10a00b08e2afcce7a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Time Factors
104 rdf:type schema:DefinedTerm
105 N82aa5b93d3ef4a58a982c8a91a59772b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Surveys and Questionnaires
107 rdf:type schema:DefinedTerm
108 N83aeecefdd8c4f99ab06e863776776e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Prospective Studies
110 rdf:type schema:DefinedTerm
111 N8a23f67906a04f1680a8a09eab07212a rdf:first sg:person.01274333640.26
112 rdf:rest N8e70e3a3b67146cfa7fee1ed256c275e
113 N8e70e3a3b67146cfa7fee1ed256c275e rdf:first sg:person.01214767574.40
114 rdf:rest rdf:nil
115 N9730d7bc85ab4e4d9c7c22bfc5af31cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Glucocorticoids
117 rdf:type schema:DefinedTerm
118 N9a5dfbb6173847da890dce2c4942512d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Acetates
120 rdf:type schema:DefinedTerm
121 Na49cc75a6f21499c8f0f3945952832b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Drug Therapy, Combination
123 rdf:type schema:DefinedTerm
124 Nb027673fecab4cc690226d091ccef3dc schema:name dimensions_id
125 schema:value pub.1041046874
126 rdf:type schema:PropertyValue
127 Nb2bb23f70f70490599c312ab7800c94d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Adult
129 rdf:type schema:DefinedTerm
130 Nb32337e4f53e4130a454d7f9116435c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Dose-Response Relationship, Drug
132 rdf:type schema:DefinedTerm
133 Nd0e1e409b0bf4913a4f808ce8ff7350e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Adolescent
135 rdf:type schema:DefinedTerm
136 Neee3b8fdcbab48fe837bcfc59af5f32c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Asthma
138 rdf:type schema:DefinedTerm
139 Nf8961401df4845308f20c7ac037d08a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Quinolines
141 rdf:type schema:DefinedTerm
142 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
143 schema:name Medical and Health Sciences
144 rdf:type schema:DefinedTerm
145 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
146 schema:name Cardiorespiratory Medicine and Haematology
147 rdf:type schema:DefinedTerm
148 sg:journal.1112076 schema:issn 1198-2241
149 1916-7245
150 schema:name Canadian Respiratory Journal
151 rdf:type schema:Periodical
152 sg:person.010455635571.89 schema:affiliation https://www.grid.ac/institutes/grid.417373.5
153 schema:familyName Kaplan
154 schema:givenName Alan
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010455635571.89
156 rdf:type schema:Person
157 sg:person.01214767574.40 schema:affiliation https://www.grid.ac/institutes/grid.14709.3b
158 schema:familyName Sampalis
159 schema:givenName John S
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214767574.40
161 rdf:type schema:Person
162 sg:person.01274333640.26 schema:affiliation https://www.grid.ac/institutes/grid.292545.d
163 schema:familyName Koch
164 schema:givenName Caroline
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274333640.26
166 rdf:type schema:Person
167 sg:person.01353722471.20 schema:affiliation https://www.grid.ac/institutes/grid.25073.33
168 schema:familyName McIvor
169 schema:givenName R Andrew
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353722471.20
171 rdf:type schema:Person
172 https://www.grid.ac/institutes/grid.14709.3b schema:alternateName McGill University
173 schema:name Faculty of Medicine, McGill University, Montreal, Quebec, Canada
174 JSS Medical Research Inc., Montreal, Canada
175 rdf:type schema:Organization
176 https://www.grid.ac/institutes/grid.25073.33 schema:alternateName McMaster University
177 schema:name Firestone Institute of Respiratory Health, McMaster University, Hamilton, Canada
178 rdf:type schema:Organization
179 https://www.grid.ac/institutes/grid.292545.d schema:alternateName Merck (Canada)
180 schema:name Merck Frosst Canada Limited, Kirkland, Canada
181 rdf:type schema:Organization
182 https://www.grid.ac/institutes/grid.417373.5 schema:alternateName York Central Hospital
183 schema:name York Central Hospital, Richmond Hill, Ontario, Canada
184 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...